Arima Genomics

The new firm, Aventa Genomics, will offer through its Orlando lab a clinical next-generation sequencing test for gene fusions, translocations, and rearrangements.

Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.

Pierian, now a part of Velsera, is integrating Arima's gene fusion sequencing technology into its NGS analysis, interpretation, and reporting hub.